On the other hand, a non-selective inhibitor, MLi-2 at 10 nM and above, demonstrated almost complete pSer935 LRRK2 inhibition, in both G2019S and WT-LRRK2 overexpression systems and in human derived healthy controls and G2019S LRRK2 PD patient cells; not surprisingly based on previous findings44,49,51. Here, LRRK2 is linked to Parkinson disease.